Cargando…

What Multiple Myeloma With t(11;14) Should Be Classified Into in Novel Agent Era: Standard or Intermediate Risk?

OBJECTIVE: To investigate the prognostic value of t(11;14) for de novo multiple myeloma (MM) patients in novel agent era. METHODS: A total of 455 patients with fluorescence in situ hybridization (FISH), before treatments from three hospitals in China, were included in the study. All patients receive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Wen, Du, Juan, Liu, Junru, Zhou, Huixing, Zhang, Zhiyao, Jian, Yuan, Yang, Guangzhong, Wang, Guorong, Tian, Ying, Li, Yanchen, Wu, Yin, Fu, Weijun, Li, Juan, Chen, Wenming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649769/ https://www.ncbi.nlm.nih.gov/pubmed/33194599 http://dx.doi.org/10.3389/fonc.2020.538126

Ejemplares similares

CD20 expression: A risk stratification factor for newly diagnosed multiple myeloma with t(11;14)
por: Jian, Yuan, et al.
Publicado: (2022)

Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era
por: Zhou, Huixing, et al.
Publicado: (2023)

Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China
por: Gao, Wen, et al.
Publicado: (2020)

Characteristics and Risk Factors of Ultra-High-Risk Patients with Newly Diagnosed Multiple Myeloma
por: Geng, Chuanying, et al.
Publicado: (2023)

Multiple myeloma with t(11;14): impact of novel agents on outcome
por: Puertas, Borja, et al.
Publicado: (2023)

Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation
por: Geng, Chuanying, et al.
Publicado: (2022)

Incidence and effect of secondary cardiac amyloidosis on outcomes of patients with t(11;14) multiple myeloma
por: Wang, Jinghua, et al.
Publicado: (2022)

The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma
por: Geng, Chuanying, et al.
Publicado: (2021)

Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation
por: Diamantidis, Michael D., et al.
Publicado: (2022)

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
por: Nguyen, Nina, et al.
Publicado: (2022)

Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
por: Kaufman, Jonathan L., et al.
Publicado: (2021)

Palbociclib regulates the expression of dihydrofolate reductase and the cell cycle to inhibit t (11;14) multiple myeloma
por: Wang, Yazhu, et al.
Publicado: (2022)

Is t(11;14)(q13;q32) good or bad for newly diagnosed multiple myeloma?
por: Liu, Yang, et al.
Publicado: (2023)

Venetoclax for the treatment of translocation (11;14) AL amyloidosis
por: Sidiqi, M. Hasib, et al.
Publicado: (2020)

Echocardiography‐defined pulmonary hypertension is an adverse prognostic factor for newly diagnosed multiple myeloma patients
por: Jian, Yuan, et al.
Publicado: (2022)

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma
por: Pan, Darren, et al.
Publicado: (2021)

Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers
por: Szita, Virág Réka, et al.
Publicado: (2022)

Real‐world data on safety and efficacy of venetoclax‐based regimens in relapsed/refractory t(11;14) multiple myeloma
por: Basali, Diana, et al.
Publicado: (2020)

Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2022)

Recombinant human thrombopoietin improves the efficacy of intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor in mobilizing peripheral blood stem cells in patients with multiple myeloma: A cohort study
por: Wang, Guorong, et al.
Publicado: (2017)

Near tetrapoloid karyotype with translocation t(11;14) in a Moroccan patient with amyloid light-chain amyloidosis and multiple myeloma
por: Hamdaoui, Hasna, et al.
Publicado: (2020)

Multiple myeloma with extramedullary plasmacytoma invading the skin and eyeballs following autologous stem cell transplantation: A case report
por: YANG, GUANGZHONG, et al.
Publicado: (2013)

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
por: Touzeau, C, et al.
Publicado: (2014)

Multiple myeloma with t(11;14)‐associated immature phenotype has lower CD38 expression and higher BCL2 dependence
por: Kitadate, Akihiro, et al.
Publicado: (2021)

The CCND1 870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma
por: Weinhold, Niels, et al.
Publicado: (2013)

Translocation t(11;14) (q13;q32) and genomic imbalances in multi-ethnic multiple myeloma patients: a Malaysian study
por: Ni, Ivyna Bong Pau, et al.
Publicado: (2012)

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
por: Bahlis, Nizar J., et al.
Publicado: (2021)

P832: PROSPECTIVE REAL-WORLD EVALUATION OF THE PREVALENCE OF T(11;14) IN MULTIPLE MYELOMA: THIRD INTERIM ANALYSIS FROM THE MEDICI STUDY
por: Gavriatopoulou, Maria, et al.
Publicado: (2023)

T cell acute lymphoblastic leukemia with t(11;14)(p13;q11) and trisomy 8
por: Safavi, Moeinadin, et al.
Publicado: (2021)

Venetoclax in combination with chidamide and dexamethasone in relapsed/refractory primary plasma cell leukemia without t(11;14): A case report
por: Yang, Yang, et al.
Publicado: (2021)

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
por: Premkumar, Vikram J., et al.
Publicado: (2021)

Mantle cell lymphoma negative for t(11,14) involving the kidneys: a case report
por: Nassereldine, Hasan, et al.
Publicado: (2022)

IgE Plasma Cell Leukemia Harboring t(11;14) and 1q Amplification
por: Nakahara, Wataru, et al.
Publicado: (2023)

Retrospective analysis of 264 multiple myeloma patients
por: GENG, CHUANYING, et al.
Publicado: (2013)

Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity
por: Todoerti, Katia, et al.
Publicado: (2021)

The prognostic impact of t(11;14) in multiple myeloma: A real‐world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR)
por: Lim, Kenneth JC, et al.
Publicado: (2023)

SOX11 expression as a MRD molecular marker for MCL in comparison with t(11;14) and IGH rearrangement
por: Szostakowska, Małgorzata, et al.
Publicado: (2018)

Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma
por: Dalland, Joanna C., et al.
Publicado: (2021)

Persistence of a t(11;14)‐positive clone in a patient with mantle cell lymphoma for 20 years
por: Otsuka, Yasuyuki, et al.
Publicado: (2017)

Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature
por: Abuelgasim, Khadega A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i3hcb2gdlrcjq8kmgv0mk9kq1l